Financial Ratios Acorda Therapeutics OTC Markets
Stocks
ACOR
US00484M7002
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-10.00% | -99.91% |
| 24-08-13 | First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc. | CI |
| 24-08-07 | Modified First Amended Joint Liquidation Plan Approved for Acorda Therapeutics, Inc. | CI |
| Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -6.94 | -7.55 | -8.19 | -6.14 | -5.77 | |||||
Return on Total Capital | -9.28 | -9.85 | -10.37 | -8.52 | -9.71 | |||||
Return On Equity % | -59.16 | -36.3 | -53.43 | -53.86 | 786.07 | |||||
Return on Common Equity | -59.16 | -36.3 | -53.43 | -53.86 | 786.07 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 81.89 | 63.27 | 60.79 | 69.52 | 82.63 | |||||
SG&A Margin | 98.67 | 99.74 | 92.2 | 89.41 | 76.25 | |||||
EBITDA Margin % | -42.95 | -29.85 | -29.17 | -7.65 | 7.14 | |||||
EBITA Margin % | -47.28 | -36.47 | -31.41 | -9.3 | 6.38 | |||||
EBIT Margin % | -60.6 | -56.58 | -55.24 | -35.24 | -19.78 | |||||
Income From Continuing Operations Margin % | -141.87 | -65.11 | -80.54 | -55.59 | -214.95 | |||||
Net Income Margin % | -141.87 | -65.11 | -80.54 | -55.59 | -214.95 | |||||
Net Avail. For Common Margin % | -141.87 | -65.11 | -80.54 | -55.59 | -214.95 | |||||
Normalized Net Income Margin | -43.62 | -31.13 | -48.51 | -36.27 | -28.96 | |||||
Levered Free Cash Flow Margin | -87.63 | -66.5 | 56.23 | 11.02 | 17.13 | |||||
Unlevered Free Cash Flow Margin | -88.7 | -64.74 | 58.16 | 12.67 | 17.63 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.18 | 0.21 | 0.24 | 0.28 | 0.47 | |||||
Fixed Assets Turnover | 1.7 | 1.6 | 7 | 12.47 | 16.58 | |||||
Receivables Turnover (Average Receivables) | 8.46 | 7.24 | 6.94 | 7.68 | 7.55 | |||||
Inventory Turnover (Average Inventory) | 1.29 | 2.08 | 2.14 | 2.31 | 1.41 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.33 | 1.61 | 1.89 | 2.16 | 0.33 | |||||
Quick Ratio | 1.71 | 0.67 | 1.16 | 1.35 | 0.21 | |||||
Operating Cash Flow to Current Liabilities | -1.48 | -0.44 | -0.77 | -0.55 | -0.06 | |||||
Days Sales Outstanding (Average Receivables) | 43.17 | 50.58 | 52.59 | 47.51 | 48.35 | |||||
Days Outstanding Inventory (Average Inventory) | 284.02 | 175.56 | 170.3 | 158.08 | 258.16 | |||||
Average Days Payable Outstanding | 441.42 | 117.87 | 103.7 | 124.24 | 177.48 | |||||
Cash Conversion Cycle (Average Days) | -114.23 | 108.27 | 119.2 | 81.35 | 129.03 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 88.16 | 115.65 | 129.29 | 184.7 | -120.85 | |||||
Total Debt / Total Capital | 46.85 | 53.63 | 56.39 | 64.87 | 579.51 | |||||
LT Debt/Equity | 81.99 | 79.8 | 120.92 | 183.05 | -2 | |||||
Long-Term Debt / Total Capital | 43.57 | 37.01 | 52.74 | 64.3 | 9.61 | |||||
Total Liabilities / Total Assets | 61.13 | 62.39 | 66.82 | 76.33 | 245.55 | |||||
EBIT / Interest Expense | -5.33 | -2.83 | -2.37 | -1.38 | -0.74 | |||||
EBITDA / Interest Expense | -3.18 | -1.09 | -0.89 | -0.11 | 0.33 | |||||
(EBITDA - Capex) / Interest Expense | -7.31 | -1.23 | -0.89 | -0.11 | 0.32 | |||||
Total Debt / EBITDA | -3.94 | -8.26 | -7.34 | -53.68 | 18.4 | |||||
Net Debt / EBITDA | -2.13 | -6.12 | -5.63 | -42.03 | 15.51 | |||||
Total Debt / (EBITDA - Capex) | -1.71 | -7.3 | -7.3 | -51.51 | 18.88 | |||||
Net Debt / (EBITDA - Capex) | -0.93 | -5.41 | -5.59 | -40.33 | 15.92 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -59.19 | -20.5 | -15.62 | -8.14 | -0.79 | |||||
Gross Profit, 1 Yr. Growth % | -57.85 | -2.11 | -18.93 | 5.05 | 17.49 | |||||
EBITDA, 1 Yr. Growth % | -178.28 | -44.75 | -17.54 | -75.89 | -196.84 | |||||
EBITA, 1 Yr. Growth % | -194.28 | -38.67 | -27.34 | -72.81 | -169.96 | |||||
EBIT, 1 Yr. Growth % | -223.02 | -25.77 | -17.62 | -41.39 | -43.92 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -910.42 | -63.51 | 4.38 | -36.59 | 283.6 | |||||
Net Income, 1 Yr. Growth % | -910.42 | -63.51 | 4.38 | -36.59 | 283.6 | |||||
Normalized Net Income, 1 Yr. Growth % | -275.04 | -43.27 | 31.49 | -31.33 | -20.43 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -909.86 | -64.22 | -20.54 | -65.83 | 212.1 | |||||
Accounts Receivable, 1 Yr. Growth % | -5.75 | -8.56 | -15.8 | -18.44 | 24.75 | |||||
Inventory, 1 Yr. Growth % | -13.07 | 13.7 | -35.32 | -31.25 | 26.69 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 174.26 | -84.49 | -56.76 | -29.13 | -20.15 | |||||
Total Assets, 1 Yr. Growth % | -38.47 | -20.89 | -28.01 | -13.15 | -72.57 | |||||
Tangible Book Value, 1 Yr. Growth % | -7.24 | 41 | 43.26 | 14.4 | -14.43 | |||||
Common Equity, 1 Yr. Growth % | -49.21 | -23.44 | -36.49 | -38.05 | -268.72 | |||||
Cash From Operations, 1 Yr. Growth % | -185 | -52.4 | -32.22 | -49.4 | -33.17 | |||||
Capital Expenditures, 1 Yr. Growth % | 171.32 | -95.15 | -96.24 | -17.58 | 94.12 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -258.22 | -39.67 | -171.35 | -81.99 | 51.94 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -263.72 | -41.97 | -175.8 | -79.99 | 36.36 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -42.81 | -43.04 | -18.1 | -11.96 | -4.53 | |||||
Gross Profit, 2 Yr. CAGR % | -42.49 | -49.12 | -10.92 | -7.71 | 11.3 | |||||
EBITDA, 2 Yr. CAGR % | -21.96 | -34.24 | -32.5 | -55.41 | -52.76 | |||||
EBITA, 2 Yr. CAGR % | -18.28 | -23.96 | -33.25 | -55.55 | -56.99 | |||||
EBIT, 2 Yr. CAGR % | 1.83 | -4.44 | -21.8 | -30.52 | -42.88 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 10.55 | 71.96 | -38.29 | -18.65 | 55.96 | |||||
Net Income, 2 Yr. CAGR % | 10.55 | 71.96 | -38.29 | -18.65 | 55.96 | |||||
Normalized Net Income, 2 Yr. CAGR % | 19.92 | -0.35 | -13.63 | -4.97 | -26.24 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 8.77 | 70.06 | -46.68 | -47.9 | 1.97 | |||||
Accounts Receivable, 2 Yr. CAGR % | -47.92 | -7.16 | -12.26 | -17.13 | 0.87 | |||||
Inventory, 2 Yr. CAGR % | -17.99 | -0.58 | -14.24 | -33.32 | -6.67 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 112.75 | -34.78 | -74.1 | -44.64 | -24.77 | |||||
Total Assets, 2 Yr. CAGR % | -18.3 | -30.23 | -24.53 | -20.93 | -51.19 | |||||
Tangible Book Value, 2 Yr. CAGR % | -31.88 | 14.37 | 42.12 | 28.02 | -1.06 | |||||
Common Equity, 2 Yr. CAGR % | -22.69 | -37.64 | -30.27 | -37.27 | 2.23 | |||||
Cash From Operations, 2 Yr. CAGR % | 14.87 | -36.39 | -43.2 | -41.44 | -41.84 | |||||
Capital Expenditures, 2 Yr. CAGR % | 157.03 | -63.71 | -95.73 | -82.4 | 26.49 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 38.73 | -2.3 | -34.39 | -64.15 | -47.31 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 39.96 | -2.53 | -33.68 | -61.05 | -47.44 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -28.19 | -36.17 | -35.07 | -14.9 | -8.38 | |||||
Gross Profit, 3 Yr. CAGR % | -27.38 | -41.21 | -40.57 | -5.88 | 0.14 | |||||
EBITDA, 3 Yr. CAGR % | 91.32 | -30.45 | -29.09 | -52.11 | -43.12 | |||||
EBITA, 3 Yr. CAGR % | 110.29 | -25.73 | -25.1 | -50.52 | -48.77 | |||||
EBIT, 3 Yr. CAGR % | 128.44 | -8.35 | -9.05 | -28.97 | -35.46 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 97.18 | -23.6 | 45.6 | -37.73 | 36.42 | |||||
Net Income, 3 Yr. CAGR % | 99.04 | -23.6 | 45.6 | -37.73 | 36.42 | |||||
Normalized Net Income, 3 Yr. CAGR % | 110.04 | -6.56 | 9.3 | -19.99 | -10.56 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 95.9 | -24.96 | 31.96 | -54.03 | -6.16 | |||||
Accounts Receivable, 3 Yr. CAGR % | -24.95 | -37.17 | -10.14 | -14.37 | -5.03 | |||||
Inventory, 3 Yr. CAGR % | -16.38 | -8.55 | -13.86 | -20.33 | -17.41 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 69.13 | -11.12 | -43.13 | -63.78 | -37.45 | |||||
Total Assets, 3 Yr. CAGR % | -15.86 | -19.17 | -29.5 | -20.91 | -44.44 | |||||
Tangible Book Value, 3 Yr. CAGR % | -36.57 | -13.19 | 23.28 | 32.21 | 11.93 | |||||
Common Equity, 3 Yr. CAGR % | -22.36 | -22.94 | -37.26 | -32.97 | -12.77 | |||||
Cash From Operations, 3 Yr. CAGR % | 62.9 | -14.36 | -35.03 | -45.35 | -38.8 | |||||
Capital Expenditures, 3 Yr. CAGR % | 144.43 | -31.55 | -82.96 | -88.55 | -60.82 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 28.48 | 5.11 | -12.02 | -57.36 | -41.71 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 28.67 | 4.37 | -10.36 | -55.52 | -40.61 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -13.68 | -20.86 | -24.31 | -27.41 | -24.24 | |||||
Gross Profit, 5 Yr. CAGR % | -13.26 | -24.7 | -28.21 | -29.59 | -23.62 | |||||
EBITDA, 5 Yr. CAGR % | 8.86 | -5.41 | 26.12 | -41.78 | -39.72 | |||||
EBITA, 5 Yr. CAGR % | 14.82 | 4.26 | 32.89 | -39.52 | -40 | |||||
EBIT, 5 Yr. CAGR % | 20.67 | 13.83 | 48.78 | -17.96 | -24.49 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 72.89 | 55.21 | 23.9 | -21.66 | 49.66 | |||||
Net Income, 5 Yr. CAGR % | 72.89 | 55.21 | 24.6 | -21.66 | 49.66 | |||||
Normalized Net Income, 5 Yr. CAGR % | 29.27 | 19.96 | 47.21 | -5.93 | -6.61 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 68.77 | 52.37 | 16.36 | -35.15 | 19.03 | |||||
Accounts Receivable, 5 Yr. CAGR % | -7.27 | -8.49 | -20.11 | -29.81 | -5.89 | |||||
Inventory, 5 Yr. CAGR % | -1.23 | -4.7 | -15.53 | -19.41 | -11.05 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 29.21 | -8.53 | -20.16 | -26.45 | -36.4 | |||||
Total Assets, 5 Yr. CAGR % | -5.57 | -10.65 | -19.44 | -19.88 | -39.14 | |||||
Tangible Book Value, 5 Yr. CAGR % | 3.92 | 62.27 | -12.41 | 1.4 | 12.9 | |||||
Common Equity, 5 Yr. CAGR % | -10.47 | -16.97 | -25.63 | -29.03 | -23.73 | |||||
Cash From Operations, 5 Yr. CAGR % | 11.42 | 9.65 | 6.88 | -26.44 | -37.85 | |||||
Capital Expenditures, 5 Yr. CAGR % | 77.84 | -5.81 | -51.57 | -60.24 | -62 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 14.64 | 27.76 | -1.81 | -31.65 | -28.33 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 14.51 | 26.16 | -1.29 | -29.64 | -27.6 |
- Stock Market
- Stocks
- ACOR.Q Stock
- ACOR Stock
- Financials Acorda Therapeutics
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















